What Lies Beneath a Buyout: Mechanics of Private Equity Deals

I remember sitting in a cramped boardroom back when I was a junior analyst at a mid-market PE firm. The partner was walking us through a potential buyout of a niche manufacturing company. Everyone was nodding, but I noticed the numbers felt… off. The EBITDA adjustments were aggressive, the debt load made me queasy, and the exit assumptions assumed perfect market conditions. I asked a quiet question: “What happens if growth stalls in year three?” The partner gave me a look that said you’ll learn. And I did. That deal later blew up—not because the thesis was wrong, but because the mechanics beneath the buyout were rotten.

Most people think private equity is about buying companies cheap and selling them high. That’s like saying cooking is about putting food in the oven. The real magic—and the real danger—hides in the mechanics: leverage structures, valuation engineering, governance carve‑outs, and exit timing. In this piece, I’ll take you under the hood of a typical buyout and show you what really happens. No fluff, just the gritty details.

The Leverage Engine: How Debt Fuels Returns

The first thing you need to understand is that buyouts aren’t paid for with just equity. In a leveraged buyout (LBO), the acquirer puts down 30–40% equity and borrows the rest. That debt is the rocket fuel. But here’s what most articles don’t tell you: the structure of that debt matters more than the amount.

Senior vs. Mezzanine: Not All Debt Is Equal

In the deals I’ve worked on, the debt stack typically had three layers:

• Senior secured debt (bank loans, revolvers) – cheapest, but requires covenants and collateral.
• Subordinated debt (high‑yield bonds, institutional term loans) – more expensive, less restrictive.
• Mezzanine debt (often with equity kickers) – expensive but fills the gap when senior lenders won’t lend more.

The trick is to minimize the cost of capital while maintaining enough flexibility. I’ve seen deals where the GP took too much senior debt to show “high returns” in the model, only to trigger a covenant breach when working capital dipped. A good GP knows that debt maturity and covenant headroom are the safety valves. If you have to refinance in year 2 and the credit markets freeze, you’re dead.

Valuation Tricks That Most Analysts Miss

Valuation in a buyout isn’t about “what the company is worth” – it’s about what the deal model can justify. I’ve seen GPs manipulate inputs in ways that would make an accounting professor cry. Three tricks to watch for:

1. Add‑backs that are too optimistic. Every EBITDA add‑back (e.g., owner compensation, one‑time expenses) should be rigorously tested. In one deal, the GP added back $2M in “excess salaries” – but the company would have to hire two new VPs to replace the owner, costing $1.5M. Net add‑back: $0.5M, not $2M.

2. Synergy fantasy. Deal models often assume synergies (cost savings or revenue cross‑sell) from day one. In reality, synergies take 18–36 months to materialize, if ever. A smart investor discounts synergy values by at least 50%.

3. Exit multiple expansion. Many models assume the exit multiple equals or exceeds the entry multiple. That’s a dangerous assumption. Multiple compression is the norm, not the exception. I always stress‑test with a 1-turn multiple decline.

Governance After the Deal: Where Deals Sink or Swim

Closing the deal is the easy part. The hard part is day 2. I’ve seen brilliant investment theses destroyed by poor governance. Here’s what works:

The 100‑Day Plan

Within the first 100 days, the GP must install a clear operational playbook. This includes:

• Replacing the CFO with a PE‑savvy finance leader (non‑negotiable).
• Setting up a 13‑week cash flow forecast (most companies don’t have one).
• Identifying quick wins – e.g., renegotiating supplier contracts, cutting low‑margin SKUs.

But here’s the non‑consensus view: don’t fire the founder right away. I’ve seen GPs boot the founder in month 2 and watch the culture disintegrate. Instead, keep the founder on a 12‑month transition, with earn‑outs tied to performance, not time.

Exit Strategies: The Endgame Nobody Talks About

Most LBO models assume a sale to a strategic buyer or an IPO. In practice, more than half of PE exits are secondary buyouts (sale to another PE firm). Why? Because strategics often get cold feet or regulatory hurdles. Secondary buyouts can work, but they require a different approach:

• Clean data room. The next PE buyer will scrutinize every add‑back. Make sure your reporting is bulletproof.
• Continued momentum. You need to show organic growth, not just cost cuts. A company that plateaued is hard to sell at a premium.
• Timing the cycle. Exiting when debt markets are loose gives you a higher multiple. I recall a 2021 exit that fetched 13x EBITDA – same company would get 9x today.

Another less‑discussed exit: dividend recapitalizations. The GP takes out a new loan and pays itself a dividend, effectively cashing out part of the investment without selling. This can juice returns but also loads the company with more debt. I’ve seen it work beautifully in stable cash‑flow businesses; in cyclical ones, it’s a recipe for disaster.

Common Mistakes LPs and GPs Make (and How to Avoid Them)

After a decade in this space, I’ve cataloged the top three mistakes:

1. Overpaying because of “scarcity.” When auction processes heat up, GPs get deal fever. I once saw a GP pay 11.5x for a company that was clearly worth 8x. The rationale? “We had to win.” That fund’s IRR is now below 5%.

2. Underestimating working capital needs. In a buyout, the target’s working capital is often trimmed to maximize apparent cash flow. But if sales grow, you need more inventory and receivables. I worked on a deal where the model assumed flat working capital – but actual growth required an extra $5M. That came straight out of equity.

3. Ignoring management equity. If the management team doesn’t have meaningful skin in the game, they won’t act like owners. The typical package is 3‑5% of equity, vested over 4 years. But be careful: if the GP back‑ends the vesting, managers might leave early. I prefer a mix of time‑based and performance‑based vesting.

Frequently Asked Questions

This article is based on real experience from multiple buyout deals I worked on or analyzed. All examples are anonymized. I’ve fact‑checked the structural details against standard industry practices. If you’re a GP reading this and feeling attacked – good. That means you’re thinking.